Clinical trials · New York
Relapsed or Refractory Multiple Myeloma clinical trials in New York
We’re tracking 153 recruiting relapsed or refractory multiple myeloma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
New York, New YorkAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
New York, New YorkAges 12 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
New York, New YorkAges 18 years+ - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Buffalo, New YorkAges 18 years+ - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Rockville Centre, New YorkAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
New York, New YorkAges 18 years+ - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Rochester, New YorkAges 18 years+ - NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
East White Plains, New YorkAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
New York, New YorkAges 18 years+ - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
The Bronx, New YorkAges 1–50 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
New York, New YorkAges 1–30 - NCT07477639RecruitingPhase 1/Phase 2
Testing TRX319 for worsening multiple sclerosis
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
New York, New YorkAges 18–65 - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Commack, New YorkAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
New York, New YorkAges 1–18 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
New York, New YorkAges 12–39 - NCT07497399RecruitingPhase 2
Testing a diabetes drug for weight loss in MS
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
New York, New YorkAges 18–60 - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
New York, New YorkAges 18–60 - NCT07224373RecruitingPhase 1
A study of AZD0120 for multiple sclerosis
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
New York, New YorkAges 18–60 - NCT06901687RecruitingPhase 2
Home brain stimulation for depression in MS
This study tests whether a special, gentle brain stimulation device you can use at home (called tDCS) can help improve depression symptoms in people with multiple sclerosis. You will be supervised over video during the sessions to make sure everything goes smoothly.
New York, New YorkAges 18–65 - NCT06463743RecruitingPhase 2
Metformin for aging people with MS
This study tests whether metformin, a common diabetes drug, can help people with multiple sclerosis (MS) as they age. It may be used alone or added to your current MS treatment, and the goal is to see if it slows down aging-related changes in MS.
Buffalo, New YorkAges 55–75 - NCT04810624Recruiting
Online relapse prevention program for anorexia recovery habits
This study looks at how to help people with anorexia nervosa prevent relapse by changing habits, using video visits. It may help you stay stable after weight restoration and reduce the chance of returning to eating disorder symptoms.
New York, New YorkAges 18–60 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Buffalo, New YorkAges 18 years+
Relapsed or Refractory Multiple Myeloma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Columbia University Irving Medical Center · 5 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Memorial Sloan Kettering Westchester · 3 studies
- Roswell Park Comprehensive Cancer Center · 3 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Mount Sinai Health System · 2 studies
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed or Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials in New York?
- Yes. We're currently tracking 153 recruiting relapsed or refractory multiple myeloma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.